Nordion to Release Third Quarter 2012 Financial Results

Nordion to Release Third Quarter 2012 Financial Results

Tanya Pobuda, 613-592-3400 x. 2280orAna Raman, 613-595-4580

Nordion Inc. (TSX: NDN) (NYSE: NDZ), a leading provider of products and services to the global health science market, today announced that the Company will report its third quarter 2012 financial results after market close on September 5, 2012.

The Company will also host an analyst conference call with Steve West, Chief Executive Officer and Peter Dans, Chief Financial Officer, to discuss the results. The call will be webcast live on September 6, 2012 at 10:00 a.m. EST.

Interested parties may access the live webcast of the conference call from the Nordion website at . To participate, please dial 1-866-225-0198 (toll-free North America) or 416-340-8061 (International). Following the call, an audio archive will be available on the website at .

Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that provides market-leading products used for the prevention, diagnosis and treatment of disease. We are a leading provider of medical isotopes, targeted therapies and sterilization technologies that benefit the lives of millions of people in more than 60 countries around the world. Our products are used daily by pharmaceutical and biotechnology companies, medical-device manufacturers, hospitals, clinics and research laboratories. Nordion has more than 500 highly skilled employees in three locations. Find out more at and follow us at

Suggested Articles

Passage Bio filed to raise $125 million in its IPO. Now, it has outraised that goal by $91 million with a $216 million Wall Street debut.

The ruling reflects the judge’s belief that the FDA’s interpretation of the law on clinical trial reporting “is unlawful and must be set aside.”

Trutino will apply a platform designed to yield safer, more effective cytokines to the discovery of three oncology drugs for Boehringer.